Eintrag weiter verarbeiten
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial
Gespeichert in:
| Zeitschriftentitel: | PLOS ONE |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , |
| In: | PLOS ONE, 12, 2017, 2, S. e0169255 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Public Library of Science (PLoS)
|
| Schlagwörter: |
| author_facet |
Konde, Mandy Kader Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Mara, Doussou Barry, Abdoulaye Cone, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan Pintilie, Melania Fish, Eleanor N. Konde, Mandy Kader Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Mara, Doussou Barry, Abdoulaye Cone, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan Pintilie, Melania Fish, Eleanor N. |
|---|---|
| author |
Konde, Mandy Kader Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Mara, Doussou Barry, Abdoulaye Cone, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan Pintilie, Melania Fish, Eleanor N. |
| spellingShingle |
Konde, Mandy Kader Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Mara, Doussou Barry, Abdoulaye Cone, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan Pintilie, Melania Fish, Eleanor N. PLOS ONE Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial Multidisciplinary |
| author_sort |
konde, mandy kader |
| spelling |
Konde, Mandy Kader Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Mara, Doussou Barry, Abdoulaye Cone, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan Pintilie, Melania Fish, Eleanor N. 1932-6203 Public Library of Science (PLoS) Multidisciplinary http://dx.doi.org/10.1371/journal.pone.0169255 <jats:p>To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our <jats:italic>in vitro</jats:italic> evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN β-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN β-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN β-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN β-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN β-1a treatment were ~ 1.5–1.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN β-1a.</jats:p> Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial PLOS ONE |
| doi_str_mv |
10.1371/journal.pone.0169255 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTM3MS9qb3VybmFsLnBvbmUuMDE2OTI1NQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTM3MS9qb3VybmFsLnBvbmUuMDE2OTI1NQ |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Public Library of Science (PLoS), 2017 |
| imprint_str_mv |
Public Library of Science (PLoS), 2017 |
| issn |
1932-6203 |
| issn_str_mv |
1932-6203 |
| language |
English |
| mega_collection |
Public Library of Science (PLoS) (CrossRef) |
| match_str |
konde2017interferonb1aforthetreatmentofebolavirusdiseaseahistoricallycontrolledsinglearmproofofconcepttrial |
| publishDateSort |
2017 |
| publisher |
Public Library of Science (PLoS) |
| recordtype |
ai |
| record_format |
ai |
| series |
PLOS ONE |
| source_id |
49 |
| title |
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_unstemmed |
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_full |
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_fullStr |
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_full_unstemmed |
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_short |
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_sort |
interferon β-1a for the treatment of ebola virus disease: a historically controlled, single-arm proof-of-concept trial |
| topic |
Multidisciplinary |
| url |
http://dx.doi.org/10.1371/journal.pone.0169255 |
| publishDate |
2017 |
| physical |
e0169255 |
| description |
<jats:p>To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our <jats:italic>in vitro</jats:italic> evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN β-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN β-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN β-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN β-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN β-1a treatment were ~ 1.5–1.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN β-1a.</jats:p> |
| container_issue |
2 |
| container_start_page |
0 |
| container_title |
PLOS ONE |
| container_volume |
12 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343407155216400 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:51:10.989Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Interferon+%CE%B2-1a+for+the+treatment+of+Ebola+virus+disease%3A+A+historically+controlled%2C+single-arm+proof-of-concept+trial&rft.date=2017-02-22&genre=article&issn=1932-6203&volume=12&issue=2&pages=e0169255&jtitle=PLOS+ONE&atitle=Interferon+%CE%B2-1a+for+the+treatment+of+Ebola+virus+disease%3A+A+historically+controlled%2C+single-arm+proof-of-concept+trial&aulast=Fish&aufirst=Eleanor+N.&rft_id=info%3Adoi%2F10.1371%2Fjournal.pone.0169255&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343407155216400 |
| author | Konde, Mandy Kader, Baker, Darren P., Traore, Fode Amara, Sow, Mamadou Saliou, Camara, Alioune, Barry, Alpha Amadou, Mara, Doussou, Barry, Abdoulaye, Cone, Moussa, Kaba, Ibrahima, Richard, Amento Ablam, Beavogui, Abdoul Habib, Günther, Stephan, Pintilie, Melania, Fish, Eleanor N. |
| author_facet | Konde, Mandy Kader, Baker, Darren P., Traore, Fode Amara, Sow, Mamadou Saliou, Camara, Alioune, Barry, Alpha Amadou, Mara, Doussou, Barry, Abdoulaye, Cone, Moussa, Kaba, Ibrahima, Richard, Amento Ablam, Beavogui, Abdoul Habib, Günther, Stephan, Pintilie, Melania, Fish, Eleanor N., Konde, Mandy Kader, Baker, Darren P., Traore, Fode Amara, Sow, Mamadou Saliou, Camara, Alioune, Barry, Alpha Amadou, Mara, Doussou, Barry, Abdoulaye, Cone, Moussa, Kaba, Ibrahima, Richard, Amento Ablam, Beavogui, Abdoul Habib, Günther, Stephan, Pintilie, Melania, Fish, Eleanor N. |
| author_sort | konde, mandy kader |
| container_issue | 2 |
| container_start_page | 0 |
| container_title | PLOS ONE |
| container_volume | 12 |
| description | <jats:p>To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our <jats:italic>in vitro</jats:italic> evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN β-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN β-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN β-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN β-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN β-1a treatment were ~ 1.5–1.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN β-1a.</jats:p> |
| doi_str_mv | 10.1371/journal.pone.0169255 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTM3MS9qb3VybmFsLnBvbmUuMDE2OTI1NQ |
| imprint | Public Library of Science (PLoS), 2017 |
| imprint_str_mv | Public Library of Science (PLoS), 2017 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 1932-6203 |
| issn_str_mv | 1932-6203 |
| language | English |
| last_indexed | 2024-03-01T16:51:10.989Z |
| match_str | konde2017interferonb1aforthetreatmentofebolavirusdiseaseahistoricallycontrolledsinglearmproofofconcepttrial |
| mega_collection | Public Library of Science (PLoS) (CrossRef) |
| physical | e0169255 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Public Library of Science (PLoS) |
| record_format | ai |
| recordtype | ai |
| series | PLOS ONE |
| source_id | 49 |
| spelling | Konde, Mandy Kader Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Mara, Doussou Barry, Abdoulaye Cone, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan Pintilie, Melania Fish, Eleanor N. 1932-6203 Public Library of Science (PLoS) Multidisciplinary http://dx.doi.org/10.1371/journal.pone.0169255 <jats:p>To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our <jats:italic>in vitro</jats:italic> evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN β-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN β-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN β-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN β-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN β-1a treatment were ~ 1.5–1.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN β-1a.</jats:p> Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial PLOS ONE |
| spellingShingle | Konde, Mandy Kader, Baker, Darren P., Traore, Fode Amara, Sow, Mamadou Saliou, Camara, Alioune, Barry, Alpha Amadou, Mara, Doussou, Barry, Abdoulaye, Cone, Moussa, Kaba, Ibrahima, Richard, Amento Ablam, Beavogui, Abdoul Habib, Günther, Stephan, Pintilie, Melania, Fish, Eleanor N., PLOS ONE, Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial, Multidisciplinary |
| title | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_full | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_fullStr | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_full_unstemmed | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_short | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| title_sort | interferon β-1a for the treatment of ebola virus disease: a historically controlled, single-arm proof-of-concept trial |
| title_unstemmed | Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial |
| topic | Multidisciplinary |
| url | http://dx.doi.org/10.1371/journal.pone.0169255 |